Quality of Life in Epilepsy-89 (QOLIE-89)
- Introduced by
- Orrin Devinsky, NYU
- Year
- 1995
- Type
- Self-report questionnaire
- Family
- disease-specific quality of life
What does it do?
The QOLIE-89 is a comprehensive disease-specific quality-of-life instrument developed specifically for people with epilepsy.
Introduced by Devinsky and colleagues in 1995, it captures the broad impact of epilepsy on physical, emotional, social, and cognitive functioning. With 89 items organized into 17 distinct domains, it remains one of the most detailed QoL assessments for epilepsy and is widely used in clinical trials, health services research, and outcome monitoring.
The intuition behind the method
Epilepsy's impact on quality of life extends far beyond seizure control. People with epilepsy often experience stigma, employment barriers, driving restrictions, medication side effects, and concerns about sudden death. Generic QoL measures miss these epilepsy-specific burdens. QOLIE-89 captures all domains essential to living with epilepsy: seizure worry, medication effects, cognitive changes, social limitations, role function, and emotional well-being. The 17-domain structure recognizes that seizure frequency and severity alone do not determine QoL; rather, patient perception across multiple life areas is paramount.
History
QOLIE-89 was developed by Orrin Devinsky at New York University in collaboration with Barbara Vickrey and colleagues at UCLA in 1995 and published in Epilepsia. It was specifically designed to address limitations of generic QoL instruments in capturing the unique burden of epilepsy on patients' lives. The instrument underwent rigorous psychometric testing in large epilepsy cohorts and has been translated and validated in 30+ languages. A shorter 31-item version (QOLIE-31) was later derived for use when administration time must be minimized. The original QOLIE-89 remains the gold standard for detailed epilepsy-specific QoL assessment and is recommended by epilepsy professional societies worldwide.
When to use it
QOLIE-89 is the preferred instrument for comprehensive QoL assessment in epilepsy clinical trials, particularly when evaluating new antiepileptic drugs or surgical interventions where side effects and patient perception matter. It is valuable in longitudinal cohort studies tracking QoL trajectories across years, routine clinical practice for detailed patient-reported outcomes monitoring, health services research evaluating rehabilitation, employment support, or psychosocial interventions, and comparative effectiveness studies. Less suitable when only brief screening is needed (shorter QOLIE-31 may be preferable) or when rapid serial assessments are required (burden of 89 items may be prohibitive).
Limitations and considerations
- 89 items require substantial completion time (20-25 minutes), leading to potential respondent fatigue in some settings
- Requires interpretation of 17 separate domain scores rather than a single summary metric, which may be less convenient in routine clinic
- Some domains (e.g., Driving Concern) may be less relevant to patients unable to drive at baseline
- Minimal Clinically Important Difference (MCID) varies by domain and population; not all have well-established thresholds
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- 17 domains provide granular understanding of which aspects of life are most affected by epilepsy, enabling targeted intervention
- Comprehensive coverage of epilepsy-specific concerns (seizure worry, driving, medication side effects, stigma) often missed by generic QoL instruments
- Well-validated across diverse epilepsy populations (focal and generalized, controlled and uncontrolled seizures, various ages)
- Strong psychometric properties with documented internal consistency, test-retest reliability, and sensitivity to clinical change
- Widely translated and used internationally, facilitating multi-center trials and cross-cultural research
Applications
- Clinical trials of new antiepileptic drugs or surgical epilepsy treatment to measure patient-perceived benefit independent of seizure reduction alone
- Longitudinal outcome studies examining how QoL evolves after epilepsy surgery, drug initiation, or lifestyle interventions over months to years
- Health services evaluation assessing impact of psychoeducational programs, vocational rehabilitation, or peer support on epilepsy patients' QoL
- Comparative effectiveness research determining which treatment pathways (monotherapy vs. polytherapy, medical vs. surgical) optimize QoL across epilepsy populations
- Routine clinical monitoring in specialized epilepsy centers to track individual patient progress and identify modifiable QoL concerns (e.g., medication side effects, stigma)
How it works
How it works
QOLIE-89 is a self-administered questionnaire comprising 89 items presented with Likert-type response scales (typically 1-5 or similar anchors). Administration time is approximately 20-25 minutes. The patient responds without time constraint; no clinical training is required. Suitable for ages 18 and older with confirmed epilepsy diagnosis. Items are phrased in patient-friendly language covering daily life experiences. May be completed on paper or electronically.
Items are aggregated into 17 domains: Seizure Worry, Overall Quality of Life, Emotional Well-Being, Energy/Fatigue, Cognitive Function, Medication Effects, Social Function, Driving Concern, Work/School Performance, Stigma, Overall Health Perception, Sexual Functioning, Pain/Discomfort, Financial Concern, Social Support, and two additional specific concern domains. Each domain is scored on a 0-100 scale independently (after reverse-scoring where applicable). No single composite total is computed; instead, each of the 17 domains is interpreted separately. Higher scores indicate better quality of life.
All 17 domain scores range from 0-100, with higher values indicating better QoL in that area. There are no established universal clinical cutoff thresholds; interpretation is typically comparative. Within-patient change over time is a key metric—a decline of 10-15 points on Seizure Worry or Emotional Well-Being may suggest meaningful deterioration warranting clinical attention. Between-group comparisons (treatment vs. control) use effect sizes. Reference data from epilepsy cohorts can guide interpretation; for example, mean Seizure Worry scores of 70+ suggest significant worry even when seizures are controlled.
Common pitfalls
- Do not aggregate all 17 domain scores into a single total; each domain has independent clinical meaning and interpretation
- Do not use QOLIE-89 as a measure of seizure control or disease activity; it measures perceived quality of life only, not seizure frequency
- Avoid administering during acute postictal confusion or in severely impaired patients; timing should ensure clear cognition and comprehension
- Do not compare scores between languages without verifying psychometric equivalence; translations may have different psychometric properties
Frequently asked questions
Should I use QOLIE-89 or the shorter QOLIE-31?
QOLIE-89 provides 17 domain scores and detailed assessment; QOLIE-31 (derived subset) is briefer (about 10 minutes) and suitable for routine clinic. Use QOLIE-89 in research trials or when comprehensive QoL profiling is needed. Use QOLIE-31 for rapid screening or when respondent burden must be minimized. Both correlate well with each other; the choice depends on context and available time.
Is a score of 50 on the Seizure Worry domain considered good or concerning?
A score of 50 (on a 0-100 scale) indicates moderate worry about seizures. Higher scores (70+) suggest well-managed worry despite living with epilepsy; lower scores (0-30) suggest substantial worry that may warrant cognitive-behavioral intervention or reassurance. Context matters—a patient with daily uncontrolled seizures at 50 on Worry may need seizure treatment optimization, whereas a seizure-free patient at 40 suggests ongoing anxiety despite control that could benefit from psychological support.
Can QOLIE-89 be used in pediatric epilepsy?
The standard QOLIE-89 is validated for ages 18+. For children and adolescents, the QOLIE-AD (adolescent) version exists and is recommended. Some adult centers have used adapted QOLIE-89 in older teens (16+) with careful attention to item comprehension, but the pediatric-specific version is preferable for developmental appropriateness and validated psychometrics.
How do I interpret a large drop in Medication Effects score between two administrations?
A significant decline in Medication Effects domain (e.g., from 60 to 35) may indicate emergence of intolerable side effects, dose escalation, or addition of medications with greater side burden. This is a signal to review medication regimen with the patient and discuss tolerability. Combined with stable seizure control, it may warrant medication adjustment. Conversely, improvement in this domain after medication change suggests the switch was tolerated well from a QoL perspective.
Related methods
Sources
Devinsky, O., Vickrey, B. G., Cramer, J., Edwards, B., Perrine, K., Hamberger, M. J., & Towle, V. L. (1995). Development of the Quality of Life in Epilepsy Inventory. Epilepsia, 36(11), 1089-1104.
Open DOI referenceCopied.